Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection
- PMID: 21486977
- PMCID: PMC3144252
- DOI: 10.1001/jama.2011.420
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection
Abstract
Context: Since herpes simplex virus type 2 (HSV-2) antibody tests have become commercially available, an increasing number of persons have learned that they have genital herpes through serologic testing. The course of natural history of HSV-2 in asymptomatic, seropositive persons is uncertain.
Objective: To evaluate the virologic and clinical course of HSV genital shedding among individuals with symptomatic and asymptomatic HSV-2 infection.
Design, setting, and participants: Cohort of 498 immunocompetent HSV-2-seropositive persons enrolled in prospective studies of genital HSV shedding at the University of Washington Virology Research Clinic, Seattle, and Westover Heights Clinic, Portland, Oregon, between March 1992 and April 2008. Each participant obtained daily self-collected swabs of genital secretions for at least 30 days.
Main outcome measure: The rate of viral shedding measured by quantitative real-time fluorescence polymerase chain reaction for HSV DNA from genital swabs.
Results: Herpes simplex virus type 2 was detected on 4753 of 23,683 days (20.1%; 95% confidence interval [CI], 18.3%-22.0%) in 410 persons with symptomatic genital HSV-2 infection compared with 519 of 5070 days (10.2%; 95% CI, 7.7%-13.6%) in 88 persons with asymptomatic infection (P < .001). Subclinical shedding rates were higher in persons with symptomatic infection compared with asymptomatic infection (2708 of 20,735 days [13.1%; 95% CI, 11.5%-14.6%) vs 434 of 4929 days [8.8%; 95% CI, 6.3%-11.5%]) (P < .001). However, the amount of HSV detected during subclinical shedding episodes was similar (median, 4.3 [interquartile range, 3.1-5.6] log(10) copies in the symptomatic infection group vs 4.2 [interquartile range, 2.9-5.5] in the asymptomatic infection group, P = .27). Days with lesions accounted for 2045 of 4753 days (43.0%; 95% CI, 39.8%-46.5%) with genital viral shedding among persons with symptomatic genital HSV-2 infection compared with 85 of 519 days (16.4%; 95% CI, 11.2%-23.9%) among persons with asymptomatic infection (P < .001).
Conclusion: Persons with asymptomatic HSV-2 infection shed virus in the genital tract less frequently than persons with symptomatic infection, but much of the difference is attributable to less frequent genital lesions because lesions are accompanied by frequent viral shedding.
Figures



Similar articles
-
Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.Sex Transm Dis. 2007 Nov;34(11):900-7. doi: 10.1097/OLQ.0b013e318063c749. Sex Transm Dis. 2007. PMID: 17538513 Clinical Trial.
-
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.N Engl J Med. 2000 Mar 23;342(12):844-50. doi: 10.1056/NEJM200003233421203. N Engl J Med. 2000. PMID: 10727588
-
Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13. Epub 2014 Feb 19. J Virol. 2014. PMID: 24554666 Free PMC article.
-
Herpes simplex virus: the importance of asymptomatic shedding.J Antimicrob Chemother. 2000 Apr;45 Suppl T3:1-8. doi: 10.1093/jac/45.suppl_4.1. J Antimicrob Chemother. 2000. PMID: 10855766 Review.
-
Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling.Sex Transm Infect. 2009 Aug;85(4):270-5. doi: 10.1136/sti.2008.034751. Epub 2009 Feb 11. Sex Transm Infect. 2009. PMID: 19211593 Free PMC article. Review.
Cited by
-
HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.FASEB J. 2013 Jul;27(7):2584-99. doi: 10.1096/fj.12-220285. Epub 2013 Mar 18. FASEB J. 2013. PMID: 23507869 Free PMC article.
-
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.Future Virol. 2012 Apr 1;7(4):371-378. doi: 10.2217/fvl.12.22. Future Virol. 2012. PMID: 22701511 Free PMC article.
-
Successful application of prime and pull strategy for a therapeutic HSV vaccine.NPJ Vaccines. 2019 Aug 1;4:33. doi: 10.1038/s41541-019-0129-1. eCollection 2019. NPJ Vaccines. 2019. PMID: 31396405 Free PMC article.
-
Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses.J Infect Dis. 2020 Mar 28;221(8):1271-1279. doi: 10.1093/infdis/jiz199. J Infect Dis. 2020. PMID: 31016321 Free PMC article.
-
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.Vaccine. 2014 Nov 28;32(50):6733-45. doi: 10.1016/j.vaccine.2014.10.002. Epub 2014 Oct 16. Vaccine. 2014. PMID: 25446827 Free PMC article. Review.
References
-
- Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis. 1998 Dec;178(6):1795–1798. - PubMed
-
- Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010 Apr 23;59(15):456–459. - PubMed
-
- Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000 Mar 23;342(12):844–850. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous